First Trust Advisors LP Morphic Holding, Inc. Transaction History

First Trust Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $701,766 - $915,358	26,867 New	26,867 $915,000
Q3 2023 Nov 13, 2023	BUY	$21.33 - $59.42 $32,954 - $91,803	1,545 Added 1.67%	93,918 $2.15 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $3.17 Million - $5.74 Million	92,373 New	92,373 $5.3 Million
Q2 2022 Aug 12, 2022	SELL	$19.74 - $43.01 $597,312 - $1.3 Million	-30,259 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$36.25 - $52.02 $620,890 - $890,998	-17,128 Reduced 36.14%	30,259 $1.22 Million
Q4 2021 Feb 08, 2022	BUY	$43.27 - $65.72 $2.05 Million - $3.11 Million	47,387 New	47,387 $2.25 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.